Physician profile
Bryan S Weinstein
NPI 1295773034
$4,668.09
in general payments reported to CMS, 2019-2025
29 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,176 · 2020: $1,105 · 2021: $1,302 · 2022: $509 · 2023: $243 · 2024: $207 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,209.57 | 2019-2025 | Rexulti, Brintellix |
| Sunovion Pharmaceuticals INC. | $864.40 | 2019-2022 | |
| Validus Pharmaceuticals LLC | $450.91 | 2019-2021 | |
| Allergan, INC. | $322.91 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $304.45 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Abbvie INC. | $231.80 | 2021-2022 | |
| Neuronetics, INC. | $203.99 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $181.55 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.27 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.54 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $77.27 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $73.79 | 2019-2022 | |
| Eisai INC. | $54.21 | 2020-2021 | |
| Corium, LLC | $48.06 | 2022 | |
| Janssen Pharmaceuticals, INC | $47.89 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $44.84 | 2020-2021 | |
| Shire North American Group INC | $44.64 | 2019 | |
| Neurocrine Biosciences, INC. | $42.39 | 2019-2022 | |
| Adlon Therapeutics L.P. | $38.58 | 2021 | |
| Bausch Health US, LLC | $38.18 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $37.70 | 2019-2020 | |
| Alkermes, INC. | $29.50 | 2025 | Aristada, Lybalvi |
| Neos Therapeutics, Lp | $27.80 | 2019 | |
| Merck Sharp & Dohme LLC | $24.93 | 2019-2020 | |
| Livanova USA, INC. | $20.99 | 2021 | |
| Almatica Pharma LLC | $19.26 | 2021 | |
| Indivior INC. | $15.77 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.02 | 2022 | |
| Tris Pharma INC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.